BPC-157 + TB-500: The Injury Recovery Stack

What this stack does

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. Its primary mechanism is the upregulation of growth hormone receptor expression in tendon fibroblasts, alongside direct promotion of angiogenesis via nitric oxide pathways. In animal models, it has demonstrated accelerated healing in tendon, ligament, muscle, and bone tissue. Research shows it activates the FAK-paxillin pathway, which drives cell survival and migration at the injury site. The effect is predominantly local: BPC-157 works where you put it, or where it concentrates after systemic dosing.

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide found in high concentrations in blood platelets and wound fluid. Its mechanism centres on actin regulation. Thymosin Beta-4 sequesters G-actin monomers, reducing the actin gradient at the cell edge, which in turn promotes cell motility and migration. Research shows TB-500 also upregulates metalloproteinase activity, remodels extracellular matrix, and reduces inflammation in damaged tissue. Unlike BPC-157, TB-500 operates systemically: it circulates and acts on multiple injury sites simultaneously.

The combination covers both arms of soft-tissue repair. BPC-157 targets local angiogenesis and fibroblast activation at the primary injury site. TB-500 mobilises satellite cells, modulates inflammation, and promotes extracellular matrix remodelling across the broader tissue network. Preclinical data supports each compound independently; human clinical trials remain limited for both, so extrapolating directly from animal models carries inherent uncertainty. Anecdotally, users in the recovery space report faster return-to-training timelines when running both compounds together versus either alone.

Who it's for

This stack is built for men 35 and older who are dealing with soft-tissue injuries that are not resolving on standard protocols: rest, physiotherapy, NSAIDs, time. That includes partial tendon tears, chronic tendinopathy, ligament sprains that won't fully close, and muscle-belly injuries that stall mid-recovery. If you have been cleared by imaging, the structural damage is confirmed, and you are in the rehabilitation window but progress has plateaued, this is the context where BPC-157 and TB-500 become relevant.

It also fits the pattern of returning from a significant layoff. Several months off training, whether from surgery, immobilisation, or accumulated soft-tissue degradation, leaves connective tissue in a remodelling deficit. The anabolic stimulus from returning to load outpaces the tissue's capacity to adapt. That gap is where overuse injuries happen on re-entry, and where this stack addresses a real physiological problem rather than a performance shortcut.

You should not be using this stack as a substitute for structural diagnosis or physiotherapy. It is most useful as an adjunct to an active rehab programme, not a replacement for one. The evidence base, while encouraging in preclinical models, does not yet support using either compound as a standalone treatment in the absence of mechanical loading and progressive rehabilitation.

The protocol

The following protocol reflects common usage patterns in the recovery space and draws on dosing ranges studied in preclinical literature. Adjust based on body weight, injury severity, and clinical guidance.

BPC-157
Dose: 250-500 mcg per injection
Frequency: Once daily
Route: Subcutaneous injection, as close to the injury site as practically possible. Intramuscular is acceptable for deeper tissue targets.
Timing: Morning, fasted or fed (no meaningful difference reported). Consistent daily timing improves compliance.
Cycle length: 8-12 weeks on, 4-6 weeks off
Washout: Minimum 4 weeks before resuming

TB-500
Dose: 2-2.5 mg per injection (loading phase); 1-1.5 mg per injection (maintenance phase)
Frequency: Loading phase: twice weekly for weeks 1-4. Maintenance phase: once weekly for weeks 5-12.
Route: Subcutaneous injection. Injection site proximity to injury is less critical than with BPC-157 given its systemic distribution.
Timing: Any time of day. Separating from BPC-157 injection by several hours is reasonable practice, though no interaction data requires it.
Cycle length: 12 weeks total (4-week load, 8-week maintenance). Align the off period with BPC-157 washout.
Washout: 4-6 weeks minimum

Reconstitution note: Both compounds are supplied as lyophilised powder and require reconstitution with bacteriostatic water. For accurate dosing volumes, use the reconstitution calculator before drawing. Store reconstituted vials refrigerated at 2-8°C and use within 28 days.

What to expect, week by week

Side effects and safety

BPC-157: Animal studies show a favourable safety profile across a wide dose range, with no observed toxicity in standard models. Human safety data is very limited. Reported side effects in the recovery space are generally mild and include nausea (most common, typically transient in the first week), dizziness at higher doses, and injection site irritation. There is theoretical concern, given BPC-157's pro-angiogenic mechanism, that it could accelerate growth of pre-existing neoplastic tissue. This is preclinical reasoning, not confirmed human evidence, but individuals with a personal or family history of cancer should discuss this with a clinician before use.

TB-500: Thymosin Beta-4 has been studied in several small human trials for wound healing and dry eye syndrome, with no serious adverse events reported at therapeutic doses. The most commonly noted side effects are fatigue and mild head rushes around injection time, likely related to transient blood pressure changes. The same pro-angiogenic caveat applies here as with BPC-157, given Thymosin Beta-4's role in cell migration and blood vessel formation.

Combined use: No formal interaction studies exist for this combination. The risk profile when combining both compounds is additive rather than synergistic from a safety perspective, meaning you carry both compound-specific risk profiles simultaneously. There are no known pharmacokinetic interactions. The primary combined risk is the pro-angiogenic concern noted above.

Drug interactions: No established interactions with common medications. If you are taking anticoagulants, the pro-angiogenic and tissue-remodelling effects may theoretically alter bleeding dynamics. Consult your clinician.

Neither BPC-157 nor TB-500 is a prescription medication in most jurisdictions, but both are classified as research compounds and are not approved for human use by any major regulatory body. Sourcing and use carry legal and safety uncertainties. A qualified clinician familiar with peptide research compounds is the appropriate person to advise on your specific situation.

Sourcing and quality

Peptide quality varies substantially between suppliers. For both BPC-157 and TB-500, the minimum standard you should expect is third-party HPLC and mass spectrometry testing, with certificates of analysis (CoA) available for the specific batch you are purchasing. A CoA from a batch produced months prior to your order is not meaningful verification of what is in your vial.

When evaluating vials, look for: lyophilised (freeze-dried) powder that is white to off-white in appearance, free from visible particulate or discolouration. Vials should be sealed under vacuum, which you can confirm by the audible hiss when the stopper is first punctured. Cloudy or yellow-tinted solutions after reconstitution are a red flag and suggest degradation or contamination.

BPC-157 is typically supplied in 5 mg vials. TB-500 is commonly found in 2 mg or 5 mg vials. Match your vial size to your protocol to minimise reconstituted volume sitting unused in the fridge. Use the reconstitution calculator to determine exact bacteriostatic water volumes for your target concentration before you reconstitute anything.

Peptides degrade. Lyophilised powder stored at room temperature will lose potency over time. Reconstituted peptide stored above 8°C or exposed to repeated freeze-thaw cycles degrades faster. Cold chain matters from the moment of shipping to the moment of injection.